Drugs Publishes May 2026 Review on Immune-Based HIV Cure Strategies
Updated
Updated · European AIDS Treatment Group · May 10
Drugs Publishes May 2026 Review on Immune-Based HIV Cure Strategies
7 articles · Updated · European AIDS Treatment Group · May 10
An open-access review in the May 2026 issue of Drugs outlines immune-based strategies aimed at curing HIV rather than only suppressing it with antiretroviral therapy.
Two core hurdles frame the field: shrinking the reservoir of latently infected immune cells that ART cannot reach, and strengthening immune control so residual virus stays suppressed after treatment stops.
The paper synthesizes current research around those twin goals, highlighting immune-based approaches as a central path in the broader search for an HIV cure.
As a one-shot HIV cure nears, will global funding cuts stop this breakthrough from reaching the world?
With breakthroughs in gene therapy and gut bacteria, which path will deliver a scalable HIV cure first?
Scientists are unmasking HIV's hiding spots, but can our immune system truly win the final battle?
The State of HIV Cure Research in 2026: Immune Approaches, Clinical Advances, and Access Gaps
Overview
As of May 2026, the search for an HIV cure is centered on immune-based strategies, aiming to overcome the limitations of lifelong antiretroviral therapy (ART). While ART has greatly improved health and life expectancy for people living with HIV, it cannot eliminate the hidden reservoir of latently infected immune cells. This means stopping ART leads to a quick return of the virus. Current research focuses on finding ways to reduce this reservoir and boost the immune system’s ability to control HIV without daily medication, moving closer to a future where lifelong ART may no longer be necessary.